The Vetr community on Monday downgraded Celgene Corporation CELG from 4.5 stars (Strong Buy) to 4 stars (Buy). Crowd confidence was very bullish, with 100 percent of the Vetr community reporting a Buy position on the stock.
See how crowdsourced ratings could help you time the market
This upgrade came with news that Celgene would be acquiring Juno Therapeutics Inc JUNO for $9 billion in an effort to expand its cancer treatment efforts.
Despite the downgrade, the Vetr crowd remained bullish, setting a target price of $114.80, which sits well above the current share price of $102.94. Analysts were equally as bullish, with most recent estimates sitting in the $120-$160 range.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
